InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,880.00
(
-1.06%
)
Dow Jones
38,460.92
(
0.00%
)
Brent Oil
87.53
(
0.35%
)
Bitcoin
64,018.46
(
-0.42%
)
Post# of 251590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 209410

Saturday, 02/25/2017 3:19:36 PM

Saturday, February 25, 2017 3:19:36 PM

Post# of 251590

The DSMB would have no choice but to stop the trial even if there was no interim and no assigned alpha. This has happened before, although I cannot, offhand, remember the particular drugs.

It happened a couple of weeks ago with Xarelto (http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=1011065 ). The study in question had no formal interim analysis, but the DSMB came forward with a recommendation to stop the trial.

p.s. Some clinicians/KOLs oppose this kind of early stoppage (when it's not in their own trial, LOL) because they say it deprives them of important data.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up